CRSP241115P25000
- 0.00
- 0.000.00%
CRISPR Therapeutics Newsroom
Gilead, Vertex Initiated as New Big Biotech Buys at Citi
ARKK's Holdings Ranked by SA Quant Grades
Form 144 | CRISPR Therapeutics(CRSP.US) Officer Proposes to Sell 4.11 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 12, $CRISPR Therapeutics(CRSP.US)$ Officer Dr. Samarth Kulkarni intends to sell 75,000 shares of its common stock on Nov 11, with a total market value of approximately $4.1
Cathie Wood's ARK Innovation ETF Is a Trump Trade Winner as Tesla Soars. But It Still Lags the Market.
Capsida Biotherapeutics to Present New Preclinical Data for Potential Best-in-Class Friedreich's Ataxia Next-Generation Gene Therapy
Mizuho Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Positive Outlook on Crispr Therapeutics AG Driven by Strong Pricing and Strategic Partnerships
CRISPR, Beam, Other Gene Editing Names up Significantly
Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $45
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $95
CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
CRISPR Technology Market Report 2024, With Profiles of Major Players Agilent Technologies, Beam Therapeutics, Caribou Biosciences, Crispr Therapeutics, Danaher, Genscript, Lonza and More - ResearchAndMarkets.com
RBC Capital Reiterates Sector Perform on CRISPR Therapeutics, Maintains $53 Price Target
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $94
Oppenheimer Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)
Express News | CRISPR Therapeutics AG : Barclays Cuts Target Price to $55 From $59
Crispr Therapeutics AG: Hold Rating Amid Mixed Financial Performance and Clinical Developments
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Exact Sciences (EXAS) and Crispr Therapeutics AG (CRSP)
Crispr Therapeutics Price Target Maintained With a $84.00/Share by Needham